We Are the Frontier

Duracyte Secured $120 Million for Subcutaneous Implants

The Houston startup will test an implantable cell therapy in patients with peritoneal cancer starting in 2027.

Updated on Oct. 13, 2026 in Tech

Isometric editorial illustration of a sterile, sculptural medical implant device sitting on a clean, textured laboratory surface.
Houston-based Duracyte has secured $120 million to advance its subcutaneous implant technology, with clinical trials for peritoneal cancer treatment scheduled for 2027. AI Illustration. Upload story photo >

Live Poll

Would you trust a long-term under-the-skin implant over traditional repeated injection treatments for chronic conditions?

Houston-based Duracyte has announced it secured $120 million in non-dilutive funding to advance its subcutaneous implant technology. The company plans to begin a clinical trial in the first half of 2027 to test implants designed to release the checkpoint inhibitor ipilimumab.

Why it matters

The development seeks to replace traditional, repeated drug infusions and injections with a single implantable device. By enabling continuous delivery of biologics, the platform could improve patient compliance and treatment consistency for those with peritoneal cancer.

The proprietary implants consist of engineered human cells capable of secreting biologics continuously for up to one year after being placed under the skin. This system is designed to provide a sustained, localized source of therapeutic agents like ipilimumab.

The players

Duracyte

A Houston-based biotechnology company developing subcutaneous cell-based delivery systems for biologic drugs.

The details

The technology utilizes engineered human cells encapsulated within a subcutaneous implant—a device placed beneath the skin for localized delivery. These cells function as a continuous, internal pump that secretes specific biologics directly into the body. By automating the dosing process, the system aims to eliminate the need for frequent, recurring clinic visits typically required for biologic infusions.

Timeline

  1. Duracyte plans to begin its first clinical trial in the first half of 2027.

The Tech Race

The platform moves beyond standard infusion-based delivery to establish a new mode of sustained systemic administration for checkpoint inhibitors. It follows a growing field of engineered cell therapies that prioritize long-term, autonomous drug delivery over traditional clinic-based scheduling.

For patients with peritoneal cancer, this technology could eventually replace frequent, labor-intensive hospital infusions with a single, long-term subcutaneous implant. Commercial availability and specific patient eligibility criteria will not be determined until clinical trials proceed.

The takeaway

Duracyte’s funding positions the firm to test whether continuous, implant-based drug release is a viable alternative to episodic infusions. Readers should watch for trial enrollment status and initial patient outcomes reported in the first half of 2027.

Further reading

For more developments in cell-based therapies and novel delivery methods, explore the latest research in Biotech.

Source note: This article includes information reported by BioCentury.

Live Poll

Would you trust a long-term under-the-skin implant over traditional repeated injection treatments for chronic conditions?